CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-14 | LYONS GARY A Director | Option exercise · Stock option (right to buy) 10b5-1 | +8,000 | 0 | ||
| 2026-04-14 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −9 | $41.07 | $370 | 125,152 |
| 2026-04-14 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −7,239 | $41.93 | $304K | 117,913 |
| 2026-04-14 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −7,215 | $41.93 | $303K | 112,491 |
| 2026-04-14 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale | −7,215 | $41.93 | $303K | 138,608 |
| 2026-04-14 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +10,000 | $19.08 | $191K | 129,211 |
| 2026-04-14 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +20,000 | $17.96 | $359K | 149,211 |
| 2026-04-14 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +7,500 | $15.46 | $116K | 156,711 |
| 2026-04-14 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −37,500 | $41.07 | $1.5M | 119,211 |
| 2026-04-14 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −7,215 | $41.93 | $303K | 111,996 |
| 2026-04-14 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −7,500 | 37,500 | ||
| 2026-04-14 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2026-04-14 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Employee stock option (right to buy) 10b5-1 | −20,000 | 20,000 | ||
| 2026-04-13 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Grant or award 10b5-1 | +14,000 | 125,226 | ||
| 2026-04-13 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −65 | $28.85 | $2K | 125,161 |
| 2026-04-13 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award 10b5-1 | +14,000 | 119,706 | ||
| 2026-04-13 | Heerma Peter CHIEF COMMERCIAL OFFICER | Grant or award | +14,000 | 145,823 | ||
| 2026-04-13 | Dube Eric M CHIEF EXECUTIVE OFFICER | Grant or award 10b5-1 | +64,000 | 496,886 | ||
| 2026-04-13 | ROTE WILLIAM E. Chief Research Officer | Grant or award 10b5-1 | +14,000 | 123,087 | ||
| 2026-04-13 | REED ELIZABETH E Chief Legal Officer and GC | Grant or award 10b5-1 | +14,000 | 119,211 |
Page 11 of 51 · 1,020 trades